| 45.34 -0.03 (-0.07%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 54.17 | 1-year : | 63.27 |
| Resists | First : | 46.38 | Second : | 54.17 |
| Pivot price | 42.89  |
|||
| Supports | First : | 41.8 | Second : | 38.97 |
| MAs | MA(5) : | 44.94 |
MA(20) : | 42.5 |
| MA(100) : | 47.12 |
MA(250) : | 38.24 |
|
| MACD | MACD : | 0.5 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 90.5 |
D(3) : | 90.6 |
| RSI | RSI(14): 61.1  |
|||
| 52-week | High : | 55.66 | Low : | 27 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ALKS ] has closed below upper band by 21.4%. Bollinger Bands are 28.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 46.44 - 46.63 | 46.63 - 46.81 |
| Low: | 44.71 - 44.92 | 44.92 - 45.12 |
| Close: | 45.04 - 45.36 | 45.36 - 45.67 |
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Thu, 29 Oct 2026
Alkermes Q3 Preview: The Pipeline Looks Strong, But Earnings Tell Another Story - Seeking Alpha
Tue, 27 Oct 2026
Alkermes plc (ALKS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Fri, 23 Oct 2026
Alkermes plc Estimates – NASDAQ:ALKS - TradingView
Tue, 20 Oct 2026
Alkermes to Report Third Quarter Financial Results on November 3, 2026 - Business Wire
Tue, 20 Oct 2026
Press Release: Alkermes to Report Third Quarter Financial Results on November 3, 2026 - Moomoo
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 168 (M) |
| Shares Float | 155 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 107.7 (%) |
| Shares Short | 17,820 (K) |
| Shares Short P.Month | 14,720 (K) |
| EPS | 0.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.8 |
| Profit Margin | 3.9 % |
| Operating Margin | 15.5 % |
| Return on Assets (ttm) | 4.1 % |
| Return on Equity (ttm) | 3.8 % |
| Qtrly Rev. Growth | 27 % |
| Gross Profit (p.s.) | 8.64 |
| Sales Per Share | 9.95 |
| EBITDA (p.s.) | 1.69 |
| Qtrly Earnings Growth | -99.5 % |
| Operating Cash Flow | 251 (M) |
| Levered Free Cash Flow | 153 (M) |
| PE Ratio | 119.31 |
| PEG Ratio | 1.9 |
| Price to Book value | 4.19 |
| Price to Sales | 4.55 |
| Price to Cash Flow | 30.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|